You Just Heard the Supreme Court Ruled for Bayer — Here Is What That Actually Means for Your Roundup Cancer Case
If you are reading this at 2 a.m., you probably saw the headline and felt the floor drop. You used Roundup for years — maybe on a farm, maybe on a landscaping crew, maybe just on your own property every weekend. Then the doctor said non-Hodgkin lymphoma. Then you heard there were lawsuits. Then a lawyer said you might have a case. And now the Supreme Court of the United States has ruled in favor of the company that made the product, and you think it is over.
It is not over. Not for everyone. And the difference between “over” and “still alive” is something a lawyer who knows this litigation can tell you in one conversation. That is why we are writing this page — not to sell you anything, not to tell you your case is worth millions, but to give you the honest legal map of what just happened, what survives, and what you need to do right now if your case is one of the ones that can still move forward.
We are Attorney911 — The Manginello Law Firm. We handle toxic-tort and catastrophic-injury cases. Ralph Manginello has spent 27-plus years in courtrooms, including federal court. Lupe Peña spent years inside a national insurance-defense firm before crossing to this side of the table. We know how the other side prices claims, how they build defenses, and where the doors are that they hope you never find. What follows is the analysis we would give you if you were sitting across from us right now.
Which Roundup Claims Are Dead — and Which Ones Survived
Claims the ruling eliminated
The failure-to-warn theory was the most accessible liability path in Roundup litigation. It was straightforward: the company knew or should have known that glyphosate could cause cancer, and it failed to warn consumers on the product label. That theory is now preempted. If your case depends entirely on proving that Monsanto should have put a cancer warning on the bottle and did not, the Supreme Court has closed that door in every state and every federal court simultaneously.
This is a significant narrowing. The failure-to-warn theory was the spine of most of the early Roundup verdicts — the cases that produced headline numbers and put Bayer under enough pressure to commit to a multi-billion-dollar settlement framework. Without it, the legal terrain is steeper, the expert costs are higher, and the path to a jury is longer. We will not pretend otherwise.
Claims that potentially survived
Three theories remain outside the warning-label preemption scope. Each is harder than failure-to-warn was, but each is a recognized product-liability theory that does not depend on what the EPA approved for the label.
Design defect. A design-defect claim argues that the chemical formulation of Roundup is unreasonably dangerous independent of any labeling deficiency — that the product itself, as designed, poses an unreasonable risk of harm that could have been reduced or eliminated by a safer alternative design. This theory does not ask whether the label warned about cancer. It asks whether the company should have formulated the product differently, or whether a safer glyphosate formulation or delivery mechanism existed that would have reduced the carcinogenic risk. Design-defect claims face significant general-causation hurdles — you must prove that glyphosate causes non-Hodgkin lymphoma under the state’s expert-admissibility standard, which in federal court and most state courts is the Daubert standard, while a minority of states still follow the Frye standard. And you must prove that a reasonable alternative design existed. But the theory itself is not preempted by FIFRA’s labeling provisions.
Negligent testing and research misconduct. This theory is built on allegations that Monsanto manipulated, ghostwrote, or selectively cited scientific research on glyphosate’s carcinogenicity — that the company did not merely fail to warn, but actively shaped the scientific record to downplay the risk. Internal emails, research protocols, and public-relations strategy documents produced in the multidistrict litigation have already surfaced in pretrial proceedings. If a negligent-testing claim is framed independently of the label-warning theory — if it attacks the company’s conduct in the research process rather than its conduct in the labeling process — it may survive preemption. The discovery trail that powered prior punitive-damages arguments may still support a negligent-testing narrative even after the warning claim is gone.
Manufacturing defect (narrow but surviving). If a plaintiff can demonstrate that a specific lot of Roundup deviated from its intended formulation in a way that caused injury — a batch that was off-specification, contaminated, or produced with a different concentration or surfactant profile than designed — that claim remains outside the warning-label preemption scope. This theory is factually difficult to establish in mass-tort herbicide cases because most Roundup products were formulated consistently across lots. But for a plaintiff with a specific product-purchase record and a lot number, it remains a theoretically viable path.
The Defendant: Bayer AG and Monsanto — Who You Are Actually Suing
Bayer AG, the German pharmaceutical and agricultural conglomerate, acquired Monsanto Company in 2018 and assumed successor liability for all Roundup-related claims. Monsanto was the original manufacturer, registrant, and marketer of Roundup — the company that designed the product formulation, conducted or commissioned the underlying safety research, and held the EPA registration for the glyphosate label at issue. In court filings, the caption defendant is still “Monsanto Company” — the name did not change, even though the parent did.
This corporate structure matters for several reasons. First, Bayer is a balance-sheet defendant — a global corporation with resources far beyond any individual insurance policy. The $7.25 billion class-action settlement framework referenced in the reporting was a commitment Bayer made to resolve a portion of the Roundup litigation, and that framework exists separately from individual personal-injury claims. Second, Monsanto’s internal documents — the emails, research protocols, and public-relations strategy papers that have already been produced in the multidistrict litigation — are the evidentiary foundation for any surviving negligent-testing or design-defect theory. Much of that discovery has already been produced in the MDL and in state-court proceedings, though access for new plaintiffs may depend on protective-order and confidentiality regimes that limit availability. Third, the corporate-structure question — which entity employed the scientists, which entity controlled the research, which entity made the regulatory submissions to EPA — is part of the liability map for any surviving claim.
The multidistrict litigation — MDL No. 2741, In Re: Roundup Products Liability Litigation — is centralized in the Northern District of California before Judge Vince Chhabria. As of mid-2026, approximately 3,900 actions were still pending in the MDL. The ruling will narrow that docket significantly, as warning-label-based claims are dismissed, but the MDL itself is not closed — non-warning claims and the settlement framework continue to operate.
The Evidence You Need to Preserve — and How Fast It Can Disappear
Every surviving Roundup claim depends on five categories of evidence. Each has a shelf life. Some are already eroding.
Your complete exposure history. This is the foundation of specific causation in any surviving theory — how much Roundup you used, how often, for how many years, and through what route of exposure. This documentation must be reconstructed before witness memories fade and before product-purchase records are destroyed. Years of retrospective exposure documentation is inherently fragile — you are asking people to remember what they bought at a hardware store in 2007 and how many Saturdays they spent spraying fence lines. The sooner this is captured in sworn statements, the stronger it is.
Your full oncological medical records with pathology confirmation. These confirm the cancer subtype, stage at diagnosis, treatment course, and prognosis. They are essential for damages quantification and for excluding confounding causes — other risk factors that could explain your NHL independently of glyphosate. Medical records are generally stable in hospital systems, but they must be collected comprehensively before any statute of limitations expires on surviving claims. If you were diagnosed years ago and have moved, changed doctors, or had records stored in multiple systems, assembling the complete file takes time.
Monsanto and Bayer internal documents produced in MDL discovery. Internal emails, research protocols, and public-relations strategy documents may support negligent-testing or design-defect theories independent of the preempted warning claim. Much of this discovery has already been produced in the MDL and in state-court proceedings, but access depends on protective-order and confidentiality regimes that may limit availability to new plaintiffs. A lawyer already in the MDL or working with MDL counsel may have access to documents that a new entrant does not — which is one reason why moving quickly matters.
The EPA registration dossier and FIFRA label-approval history for glyphosate. These are public-record documents that establish what the EPA knew and approved regarding the Roundup label. They are stable — published regulatory documents do not disappear — but they must be analyzed carefully for any surviving regulatory-negligence or negligent-testing theory. The gap between what Monsanto told the EPA and what Monsanto’s own scientists were saying internally is where the negligent-testing case lives.
The IARC monograph and supporting scientific literature on glyphosate carcinogenicity. The IARC classification remains the primary scientific counterweight to the EPA’s position. IARC’s Group 2A classification — “probably carcinogenic to humans” — is the anchor for the general-causation opinion that your toxicologist and epidemiologist will offer under Daubert. Published scientific literature is stable, but expert reports synthesizing this science must be prepared early to survive Daubert challenges in any new filing. The defense will move to exclude your causation experts, and the strength of the IARC science plus the quality of your expert’s methodology is what defeats that motion.
The Playbook Bayer Will Run Now — and How Each Play Is Countered
The ruling changes Bayer’s litigation strategy overnight. Here is what the company will do, in order, and what each move really means for your case.
Play 1: The “Your Case Is Over” Letter
Within weeks, Bayer’s claims administrators will send letters to every current Roundup claimant whose case is based on a failure-to-warn theory. The letter will say the Supreme Court has ruled, that warning-label claims are preempted, and that your case is dismissed or will be dismissed. The tone will be final and authoritative.
The counter: the letter is partially correct and partially a negotiation tactic. If your case is exclusively a failure-to-warn claim, the letter is right — that theory is dead. But if your case can be re-theorized around design defect, negligent testing, or manufacturing defect, the letter is premature. A lawyer must read your complaint, evaluate your exposure history and medical records, and determine whether a surviving theory fits your facts before you accept the letter’s conclusion. Do not call the number on that letter. Call your own lawyer.
Play 2: The Motion to Dismiss Everything
Bayer will file motions to dismiss in the MDL and in individual state courts, arguing that the Supreme Court’s ruling effectively eliminates all Roundup claims — not just warning-label claims. They will argue that design-defect claims are really just repackaged warning claims, that negligent-testing claims depend on the same EPA-labeling framework, and that the ruling should be read broadly.
The counter: this is an overreading of the ruling, and plaintiffs’ counsel will oppose it. The Supreme Court addressed warning-label preemption specifically — it did not hold that FIFRA preempts all state-law product-liability claims against pesticide manufacturers. Design-defect claims that challenge the formulation itself, not the label, are doctrinally distinct. Negligent-testing claims that challenge the company’s research conduct, not its labeling decisions, are doctrinally distinct. Whether Bayer’s broad-reading argument succeeds in any given court is an open question — but it is not automatic, and it is not the same as the ruling itself.
Play 3: The Daubert Blitz
For any surviving claim, Bayer will file Daubert motions to exclude the plaintiff’s general-causation experts — the toxicologists and epidemiologists who would testify that glyphosate causes NHL. The argument will be straightforward: the EPA says glyphosate is not likely to be a human carcinogen, the Supreme Court just deferred to the EPA’s regulatory judgment, and therefore the plaintiff’s experts’ opinion that it is carcinogenic is unreliable and should be excluded.
The counter: the EPA’s regulatory determination and the scientific question of whether glyphosate causes NHL are not the same thing. The EPA’s position is a regulatory risk-management decision made under a specific statutory framework. IARC’s Group 2A classification is a hazard identification made by an independent international cancer agency using a different methodology. A qualified expert can rely on the IARC monograph, the peer-reviewed epidemiological literature, and the mechanistic studies to offer a causation opinion that survives Daubert — even if the EPA reached a different regulatory conclusion. The defense will fight this hard, and the outcome is case-specific and judge-specific, but the scientific record is not a blank slate for Bayer just because the EPA’s label decision was deferred to.
Play 4: The Mediation Squeeze
Bayer will use the ruling as leverage in every mediation and settlement conversation. The message will be: “Your case just got weaker. The easy theory is gone. The hard theories are expensive to litigate and uncertain. Take what we are offering, because it will only go down from here.”
The counter: the ruling does depress case values — that is real, and we will not pretend it is not. But Bayer still has billions in exposure under the existing settlement framework, still has thousands of filed cases, and still faces the reputational and financial cost of trying every surviving case one by one. A plaintiff with a strong exposure history, a confirmed NHL diagnosis, a compelling alternative-causation exclusion, and a well-pleaded design-defect or negligent-testing claim retains meaningful settlement value. The lawyer who understands the difference between a strong surviving case and a weak one is the lawyer who does not let Bayer’s mediation-squeeze turn a real case into a nominal settlement.
Play 5: The Jury Instruction Argument
If a surviving case reaches trial, Bayer will ask the judge to instruct the jury that the EPA has determined glyphosate is not likely to be a human carcinogen and that the Supreme Court has ruled on Roundup’s labeling. The defense will frame this as: the highest court in the land and the federal regulator have both spoken.
The counter: the Supreme Court ruled on preemption — a legal doctrine about who controls the label — not on whether glyphosate causes cancer. The EPA’s determination is a regulatory position, not a scientific finding beyond dispute, and IARC’s conflicting classification is admissible evidence. A careful plaintiff’s lawyer will ask the judge to frame the jury instruction accurately: the EPA approved the label without a cancer warning, but the jury is being asked about the company’s testing conduct or product design, not about the label. Voir dire must account for jury awareness of the ruling — the defense will argue that the highest court in the land has effectively ruled on Roundup’s safety, and the plaintiff must reframe the ruling as limited to label warnings while the company’s testing and research conduct remains at issue.
The Proof Story: How a Surviving Roundup Case Is Actually Built
Here is the chronological walk of how a surviving Roundup case moves from intake to resolution. This is not a summary — it is the actual sequence of work.
Week one: the preservation letter. The day you call, a litigation-hold letter goes out to Monsanto/Bayer demanding preservation of all internal documents relating to glyphosate research, testing protocols, communications with the EPA, and any documents produced in the MDL that relate to your exposure period. The letter also demands preservation of your specific purchase records if available, your employment records if your exposure was occupational, and any product formulations or lot records for the time period you used Roundup. This letter matters because it creates a legal duty to preserve evidence — and if the company lets evidence die after receiving it, the consequences in court can be severe.
Weeks two through four: the intake and exposure reconstruction. We sit down with you — in person, by phone, by video — and reconstruct your entire exposure history. When did you first use Roundup? How often? What size containers? Did you mix concentrates? Did you spray, load, or handle it? Did you wear gloves, a mask, nothing? Where did you buy it? Do you have receipts, credit-card statements, or store records? Who else witnessed your use — family members, coworkers, employers? Every detail is captured in a sworn statement before memory degrades further. We also pull your complete medical file — every pathology report, every treatment record, every scan, every blood test — and begin the alternative-causation analysis.
Months one through three: the expert selection. This is the make-or-break variable in any surviving Roundup case. We retain a board-certified toxicologist and a credentialed epidemiologist to prepare reports on general causation (glyphosate causes NHL) and specific causation (your NHL was caused by your glyphosate exposure). The IARC classification serves as the scientific anchor against the EPA’s contrary regulatory position. The experts must be qualified, their methodology must be sound, and their reports must be built to survive a Daubert challenge — because Bayer will file one, and if your experts are excluded, your case is over before it reaches a jury.
Months three through six: the complaint and filing. The complaint is drafted around surviving theories only — failure-to-warn is stripped out to avoid preemption dismissal. Design defect, negligent testing, and (where facts support it) manufacturing defect are the pleaded counts. The filing jurisdiction is selected based on state-by-state analysis of the statute of limitations, the expert-admissibility standard, the comparative-fault rule, and any damage caps. In some cases, the case is filed directly into the MDL in the Northern District of California. In others, it is filed in state court in a plaintiff-favorable jurisdiction where the surviving theories are strongest.
Months six through eighteen: discovery. Written discovery goes out — interrogatories, document requests, requests for admission. We demand the Monsanto/Bayer internal documents: research protocols, internal emails about glyphosate’s carcinogenicity, communications with the EPA, ghostwriting of scientific publications, suppression of unfavorable study results, and any internal acknowledgment of carcinogenic risk independent of label language. Depositions follow — the scientists who ran the studies, the regulatory affairs staff who communicated with the EPA, the executives who approved the public-relations strategy. The same documents that powered prior punitive-damages arguments may still support a negligent-testing narrative.
Month eighteen and beyond: resolution. Some cases settle in mediation, where the leverage is lower post-ruling but the $7.25 billion settlement framework and the remaining inventory of filed cases still create portfolio-resolution pressure on Bayer. Some cases go to trial — bellwether cases selected to test the surviving theories before a jury. And some cases are dismissed — because the surviving theory did not fit the facts, or the experts were excluded, or the statute of limitations had already run. The outcome depends on the strength of the case, the quality of the lawyers, and the willingness of the client to see a long process through.
The Scientific Battleground: IARC Versus EPA
The central scientific conflict in Roundup litigation has always been the gap between two authoritative assessments of glyphosate’s carcinogenicity.
The International Agency for Research on Cancer — IARC, the World Health Organization’s specialized cancer agency — reviewed glyphosate in 2015 and classified it as Group 2A: “probably carcinogenic to humans.” IARC’s classification is a hazard identification — it assesses whether a substance has the potential to cause cancer in humans, based on human, animal, and mechanistic evidence. IARC’s review found “limited evidence” of cancer in humans (non-Hodgkin lymphoma) and “sufficient evidence” in experimental animals.
The Environmental Protection Agency has maintained across multiple reviews that glyphosate is “not likely to be carcinogenic to humans.” The EPA’s review process under FIFRA is a risk assessment — it evaluates both the hazard and the exposure levels, and it considers the regulatory framework for acceptable risk. The EPA’s position has been challenged by scientists, advocacy groups, and some former agency advisors, but it remains the operative regulatory determination.
The Supreme Court’s ruling did not resolve this scientific conflict. It resolved the legal question of who controls the label — the EPA does, through FIFRA. But the scientific conflict between IARC and the EPA remains the evidentiary foundation for any surviving Roundup claim. Your experts will rely on the IARC classification and the supporting epidemiological literature. Bayer’s experts will rely on the EPA’s determination and the studies the EPA relied upon. The jury — if your case gets to one — will hear both sides and decide which science is more credible.
This is why expert selection is the single most important strategic decision in a surviving Roundup case. A board-certified toxicologist who can explain the IARC methodology, distinguish it from the EPA’s risk-assessment framework, and connect the mechanistic evidence to your specific NHL diagnosis is the difference between a case that survives Daubert and a case that does not.
Frequently Asked Questions
Is my Roundup case dead because of the Supreme Court ruling?
Not necessarily. The ruling eliminates failure-to-warn claims — claims that Monsanto should have put a cancer warning on the label. But claims based on design defect (the product formulation itself is unreasonably dangerous), negligent testing (the company manipulated or suppressed safety research), and manufacturing defect (a specific lot deviated from its intended formulation) may survive. Whether your specific case can be re-theorized around a surviving claim depends on your exposure history, your medical records, and the strength of the scientific evidence linking your cancer to glyphosate. A lawyer must evaluate your case under the post-ruling framework before you conclude it is over.
I already have a lawyer and a filed case — what should I do?
Call your lawyer today and ask whether your complaint is being amended to plead design defect, negligent testing, or manufacturing defect as surviving theories. If your case is exclusively a failure-to-warn claim, it will be dismissed — the question is whether your lawyer is already working on a re-pleading strategy. If the answer is uncertain, get a second opinion from a lawyer who is actively litigating in the post-ruling landscape. Courts will not grant indefinite extensions for amending complaints.
I used Roundup and have non-Hodgkin lymphoma but never filed a lawsuit — is it too late?
It may not be, but the clock is running. The statute of limitations in your state determines the deadline, and for toxic-exposure cases, many states apply a discovery rule — the clock starts when you knew or should have known that your cancer was connected to Roundup. That date varies by state and by individual circumstances. Some states also have a statute of repose that can cut off a claim even before discovery. You need to confirm the specific deadline in your state with a lawyer immediately — this is not something you can afford to guess about.
Did the Supreme Court say Roundup is safe?
No. The Supreme Court ruled on a legal doctrine called preemption — whether federal law (FIFRA, administered by the EPA) overrides state tort-law claims about pesticide labeling. The Court held that it does, at least for warning-label claims. The ruling is about who controls the label, not about whether glyphosate causes cancer. The scientific conflict between the IARC classification (“probably carcinogenic”) and the EPA position (“not likely to be carcinogenic”) remains unresolved and is still the evidentiary battleground for surviving claims.
What kind of exposure history do I need to have a viable surviving case?
The strongest surviving cases involve heavy, long-term, documented exposure — agricultural workers, professional landscapers, groundskeepers, farmers, nursery workers — people who used Roundup daily or weekly for years. Occasional residential use (spraying weeds in a driveway a few times a year) is much harder to connect to a specific cancer diagnosis, because the dose is lower and the alternative-causation arguments are stronger. But “harder” is not “impossible” — every case turns on its specific facts, and a lawyer must evaluate yours before concluding it is not viable.
What is the difference between design defect and failure to warn?
Failure to warn says: the product was dangerous and the company did not tell you about the danger on the label. Design defect says: the product itself was unreasonably dangerous as designed — the formulation, the concentration, the delivery mechanism — and a safer alternative design existed that would have reduced the risk. The first theory is about information (what the label said). The second is about the product itself (how it was made). The Supreme Court preempted the first. The second is a different legal theory that does not depend on the label.
Will Bayer still offer settlements after the ruling?
Yes, but on different terms. Bayer still faces the $7.25 billion settlement framework, still has thousands of filed cases, and still has the financial and reputational cost of trying every surviving case individually. The ruling gives Bayer leverage to drive settlement values down — but it does not eliminate the company’s incentive to resolve claims, especially claims with strong exposure histories and confirmed cancer diagnoses. A lawyer who knows the post-ruling settlement landscape can tell you whether the offer you receive is fair or whether you should push forward.
How long does a surviving Roundup case take?
A surviving individual Roundup case — one filed after the ruling on a design-defect or negligent-testing theory — can take 18 months to three years from filing to resolution, depending on the court’s docket, the complexity of the discovery, the Daubert motions, and whether the case settles or goes to trial. The MDL’s timeline is separate and may move faster or slower depending on how the transferee judge manages the post-ruling docket. This is not a fast process, and anyone who tells you otherwise is not being honest with you.
Can I still join the Roundup MDL?
The MDL — MDL No. 2741 in the Northern District of California — is still active, though the ruling will narrow its docket as warning-label claims are dismissed. Whether your case belongs in the MDL or in an individual filing in state court is a strategic decision that depends on your filing jurisdiction, the surviving theory, and your lawyer’s assessment of where your case is strongest. This is not a decision to make without counsel.
What does it cost to hire a lawyer for a surviving Roundup case?
At our firm, we work on contingency — 33.33% before trial and 40% if the case goes to trial. We do not get paid unless we win your case. The consultation is free. We serve families fully in English and in Spanish. The number is 1-888-ATTY-911 — 1-888-288-9911 — and we have live staff 24 hours a day, 7 days a week. Not an answering service. Real people who can take your call right now.
Who We Are and Why This Page Exists
This page exists because the Supreme Court ruling is going to send thousands of people to the internet at 2 a.m., searching for one answer: “Is my case over?” Most of what they will find is financial news about Bayer’s stock price and legal commentary written for other lawyers. Very little of it will be written for them — for the person who used Roundup, got cancer, and does not know whether they still have rights.
Ralph Manginello has spent 27-plus years in courtrooms, including federal court. He is admitted to the U.S. District Court for the Southern District of Texas. He was a journalist before he was a lawyer — he knows how to read a Supreme Court ruling and tell you, in plain English, what it means and what it does not. He is a member of the Texas Trial Lawyers Association and the Houston Bar Association, and he has spent his career in the courtroom, not behind a desk. You can read more about Ralph here.
Lupe Peña spent years inside a national insurance-defense firm — the rooms where adjusters and their software decided how to deny, delay, and devalue claims exactly like yours. He knows how Colossus values a claim, how reserves are set in the first 48 hours, how IME doctors are selected, and how surveillance is deployed. Now he sits on your side of the table. He is fluent in Spanish and conducts full client consultations in Spanish without an interpreter. You can read more about Lupe here.
We handle toxic tort cases and wrongful death claims — the exact kind of litigation that Roundup claims fall into. We are not the counsel of record on the Supreme Court case or on any specific Roundup incident reported in the news. What we are is a firm that understands this litigation, this ruling, and the difference between a case that is dead and a case that can still move forward. If your family lost someone to non-Hodgkin lymphoma and you believe Roundup was the cause, we can evaluate that case too — contact us and we will tell you honestly whether a surviving theory fits your facts.
This page is legal information, not legal advice. Every case turns on its own facts, and the ruling’s effect on your specific claim depends on your exposure history, your medical records, your state’s law, and the theory your lawyer pleads. Nothing on this page is a guarantee of any outcome. Past results depend on the facts of each case and do not guarantee future outcomes.
But here is what we can guarantee: the consultation is free, the call is confidential, and the person who answers the phone at 1-888-ATTY-911 is a real human being, not a recording. If you are reading this at 2 a.m. and you are scared that the Supreme Court just took away your case — call us. We will tell you the truth. And if the truth is that your case can still move forward, we will tell you how.
Hablamos Español. Lupe conducts full consultations in Spanish. Su familia no necesita un intérprete para recibir respuestas honestas sobre su caso.
1-888-ATTY-911. 1-888-288-9911. Free consultation. No fee unless we win your case.